- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
- Interventions
- ONM-501, Cemiplimab
- Drug
- Lead sponsor
- OncoNano Medicine, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 733
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Interventions
- Lifileucel (LN-144/LN-145)
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Harrison, New York • New York, New York
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Interventions
- Arm 1
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Vertigo, Dizziness
- Interventions
- VRT Care
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Peoria, Illinois • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Retinoblastoma
- Interventions
- carboplatin, vincristine sulfate
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 10 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2001
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
- Interventions
- iodine I 131 monoclonal antibody 3F8
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma
- Interventions
- Pembrolizumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Nashville, Tennessee
- Conditions
- Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more
- Conditions
- Optic Nerve Injuries, Sellar Tumor, Skull Base Neoplasms
- Interventions
- Optic Nerve Stimulation
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Strabismus
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma, Stage I Retinoblastoma, Unilateral Retinoblastoma
- Interventions
- Biospecimen Collection, Carboplatin, Etoposide, Examination Under Anesthesia, Magnetic Resonance Imaging, Melphalan, Ultrasound Biomicroscopy, Vincristine
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Uveal Melanoma
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Normal Tension Glaucoma
- Interventions
- Gingko Baloba, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Robert Ritch, MD, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Interventions
- Droxidopa, Placebo Oral Tablet
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor
- Interventions
- C7R-GD2.CART cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 74 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IV Uveal Melanoma
- Interventions
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Selumetinib, Temozolomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 32
- States / cities
- Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dementia-related Psychosis
- Interventions
- Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
- Conditions
- Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
- Interventions
- [18F]T807 ([18F]MNI-777)
- Drug
- Lead sponsor
- Molecular NeuroImaging
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration
- Interventions
- punch skin biopsy
- Procedure
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • South Euclid, Ohio
- Conditions
- Intracranial Hemorrhages, Brain Injuries, Subarachnoid Hemorrhage, Ischemic Stroke, Stroke
- Interventions
- Ultrasound, Pupilometer
- Device
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
- Interventions
- Mutation analysis
- Genetic
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 0 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor, Plexiform Neurofibroma, Optic Glioma, Neurofibroma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Weeks and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Sclerosis, Optic Neuritis
- Interventions
- Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 46 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1988
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 12 more